content_image/193857.jpg content_image/193855.jpg content_image/193854.jpg
## Bristol-Myers Squibb 

The final purchase price allocation for ZymoGenetics, Amira and Inhibitex and the preliminary purchase price allocation (pending final valuation of intangible assets and deferred income taxes) for Amylin were as follows: 

<img src='content_image/193857.jpg'>

Cash paid for the acquisition of Amylin included payments of $5,093 million to its outstanding common stockholders and $219 million to holders of its stock options and restricted stock units (including $94 million attributed to accelerated vesting that was accounted for as stock compensation expense in the third quarter of 2012). 

The results of operations from acquired companies are included in the consolidated financial statements as of the acquisition date. 

Revisions to goodwill from preliminary estimates at September 30, 2012 for Amylin relate primarily to an adjustment of the preliminary amount allocated to the fair value of acquired IPRD (decrease of $250 million) based on additional information obtained related to future cash flow projections, net of the resulting deferred tax adjustment ($99 million). 

Pro forma supplemental financial information is not provided as the impacts of the acquisitions were not material to operating results in the year of acquisition. Goodwill, IPRD and all intangible assets valued in these acquisitions are non-deductible for tax purposes . 

## $^{ }$Note 5 OTHER (INCOME)/EXPENSE 

Other (income)/expense includes: 

<img src='content_image/193855.jpg'>

## $^{ }$Note 6 RESTRUCTURING 

$^{ }$The following is the provision for restructuring: 

<img src='content_image/193854.jpg'>

